RVU — Ryvu Therapeutics SA Share News
0.000.00%
Last trade - 00:00- PLN417.09m
- PLN434.44m
- PLN62.25m
Brief: Ryvu Therapeutics Gets Approval For Phase I/II Study Of RVU120 (SEL120) In Spain
Brief: Ryvu Therapeutics Signs Annex To Framework Deal With Icon Clinical Research Which Ups Total Deal Value To EUR 5.6 Mln
Brief: Ryvu Therapeutics Says Galapagos Exercises Option To License Inflammatory Disease Drug Program
Brief: Ryvu Therapeutics Partner Menarini Group Receives FDA Orphan Drug Designation
Brief: Ryvu Therapeutics Clinical and Translational Data Is Accepted For Presentation in US
Brief: Ryvu Therapeutics Seeks 13.8 Mln Zloty Contractual Penalties from R&D Centre Contractor
Brief: Ryvu Therapeutics Q2 Net Loss Widens To 24.2 Mln Zlotys
Brief: Ryvu Therapeutics Says FDA Lifts Partial Clinical Hold On Rvu120 Phase Ib Study In Acute Myeloid Leukemia And Myelodysplastic Syndrome
Brief: Ryvu Therapeutics Got Full Approval To Conduct Phase I/II Study Of RVU120 In Patients With Relapsed/Refractory Metastatic Or Advanced Solid Tumors In Poland
Brief: Ryvu Therapeutics Says Total Non-Cash Expense From Incentive Programme Will Amount To PLN 51-62 Mln Spread Over 2021-2024
Brief: Ryvu Therapeutics Q1 Net Loss Widens To 13.6 Mln Zlotys
Brief: Ryvu Therapeutics Appoints Vatnak VAT-Ho As Chief Business Officer
Brief: Ryvu Announces Partial Clinical Hold Of Phase Ib Clinical Trial Of RVU120
Brief: Ryvu Therapeutics Signs 18.9 Mln Zloty Grant Deal For Tumor Drug Project
Brief: Ryvu Therapeutics FY Net Loss Narrows To 31.7 Mln Zlotys
Brief: Ryvu Therapeutics Signs Deal With US-based Covance
Brief: Ryvu Therapeutics Says Poland's Medicines Authority Allows For Phase I Trial Of SEL120
Brief: Ryvu Therapeutics 9-Month Net Loss Shrinks To 20.7 Mln Zlotys
Brief: Ryvu Therapeutics Revises Portfolio Of Research Projects